Examination of Fourteen Elemental Impurities in Levofloxacin Parenteral by Applying ICP-MS Technique

محورهای موضوعی :

Gopikrishna Yenduri ¹ ( Division of Chemistry, Department of S & H, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Vadlamudi, Andhra Pradesh, India – 522213 )
Srinivasu Navuluri ² ( Division of Chemistry, Department of S & H, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Vadlamudi, Andhra Pradesh, India – 522213 )

تاریخ دریافت : 1400/08/26 تاریخ پذیرش : 1401/11/23 تاریخ انتشار : 1402/09/10

کلید واژه: Impurity, ICP-MS, Levofloxacin, Metal elements, Parenteral,

چکیده مقاله :

In our work, a process for levofloxacin (LVO) digestion using the microwave digester was proposed. Simultaneous examination of fourteen metal elemental impurities (lithium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, arsenic, molybdenum, cadmium, antimony, mercury, and lead) in digested LVO sample was done by ICP-MS system. Quantification limits vary between 2.7 ppb to 3000 ppb for all studied metal elemental impurities. Linear regression analysis proved linearity from LOQ quantity level to 200% of respective metal specification quantity limitations. The slope and coefficient correlation findings for fourteen metal elemental impurities were reported to be within permissible limit values. These outcomes demonstrated that the recommended ICP-MS methodology is capable of detecting 14 metal elemental impurities. Percentage recoveries for all studied metal elemental impurities were revealed to be satisfactory with recommended ICP-MS methodology conditions. The fully validated ICP-MS technique was finally adopted for batch studies of six different LVO parenteral for the selected fourteen metal elemental impurities.

منابع و مأخذ:

1. Li G., Schoneker D., Ulman K.L., Sturm J.J., Thackery L.M., Kauffman J.F., 2015. Elemental impurities in pharmaceutical excipients. J Pharm Sci. 104(12), 4197-4206.


2. Maithani M., Raturi R., Sharma P., Gupta V., Bansal P., 20919. Elemental impurities in pharmaceutical products adding fuel to the fire. Regul Toxicol Pharmacol. 108, 104435.


3. Jenke D.R., Stults C.L., Paskiet D.M., Ball D.J., Nagao L.M., 2015. Materials in manufacturing and packaging systems as sources of elemental impurities in packaged drug products: A literature review. PDA J Pharm Sci Technol. 69(1), 1-48.


4. Jenke D., 2020. Materials in manufacturing and packaging systems as sources of elemental impurities in packaged drug products: An updated literature review. PDA J Pharm Sci Technol. 74(3), 324-347.


5. Holm R., Elder D.P., 2016. Analytical advances in pharmaceutical impurity profiling. Eur J Pharm Sci. 87, 118-135.


6. Balaram V., 2016. Recent advances in the determination of elemental impurities in pharmaceuticals – Status, challenges and moving frontiers. TrAC Trend Anal. Chem. 80, 83-95.


7. Boetzel R., Ceszlak A., Day C., Drumm P., Gil Bejar J., Glennon J., et al., 2018. An elemental impurities excipient database: A viable tool for ICH Q3D drug product risk assessment. J Pharm Sci. 107(9), 2335-2340.


8. Fliszar K.A., Walker D., Allain L., 2006. Profiling of metal ions leached from pharmaceutical packaging materials. PDA J Pharm Sci Technol. 60(6), 337-342.


9. Barin J.S., Mello P.A., Mesko M.F., Duarte F.A., Flores E.M., 2016. Determination of elemental impurities in pharmaceutical products and related matrices by ICP-based methods: a review. Anal Bioanal Chem. 408(17), 4547-4566.


10. The United States Pharmacopoeia, USP 38-NF 33, Elemental Impurities- Procedures, Chap – 233, Revis Bull Official, 2015. pp. 232–234.

11.The United States Pharmacopoeia, USP 40-NF 35, Elemental Impurities- Limits, Chap -232, Revis Bull Official, 2017. pp. 8065-8069.

12. European Pharmacopeia. Determination of elemental impurities, Vol. -I, 9^th Ed., France, 2018. pp. 5833-5836.


13. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, guideline for elemental impurities. Q3D Step. December 16, 2014.  


14. Muller A.L., Oliveira J.S., Mello P.A., Muller E.I., Flores E.M., 2015. Study and determination of elemental impurities by ICP-MS in active pharmaceutical ingredients using single reaction chamber digestion in compliance with USP requirements. Talanta. 136, 161-169.


15. Mittal M., Kumar K., Anghore D., Rawal R.K., 2017. ICP-MS: Analytical method for identification and detection of elemental impurities. Curr Drug Discov Technol. 14(2), 106-120.


16. Janchevska K., Stafilov T., Memed-Sejfulah S., Bogdanoska M., Ugarkovic S., Petrushevski G., 2020. ICH Q3D based elemental impurities study in liquid pharmaceutical dosage form with high daily intake - comparative analysis by ICP-OES and ICP-MS. Drug Dev Ind Pharm. 46(3), 456-461.


17. Krejčová A., Ludvíková I., Černohorský T., Pouzar M., 2012. Elemental analysis of nutritional preparations by inductively coupled plasma mass and optical emission spectrometry. Food Chem. 132(1), 588-596.


18. Bientinesi R., Murri R., Sacco E., 2020. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opin Pharmacother. 21(6), 637-644.


19. Ren H., Li X., Ni Z.H., Niu J.Y., Cao B., Xu J., 2017. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg day^-1) or conventional intravenous/oral levofloxacin (500 mg day^-1): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol. 49(3), 499-507.


20. Lalitha D.M., Chandrasekhar K.B., 2009. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant. J Pharm Biomed Anal. 50(5), 710-717.


21. Mehta J.D., Pancholi Y., Patel V., Kshatri N., Vyas N., 2010. Development and validation of a sensitive stability indicating method for quantification of levofloxacin related substances and degradation products in pharmaceutical dosage form. Int J Pharmtech Res. 2(3), 1932-1942.

22. Gudlawar S.K., Jaya D., Venugopal N., 2015. A selective and sensitive UPLC-MS/MS method for simultaneous determination of four GTIs in levofloxacin. Rasayan J Chem. 8(1), 47-55.


23. Sateesh J.N., Subba reddy G.V., Jayaveera K.N., Dhayalamurthi S., 2012. A validated stability-indicating isocratic LC method for levofloxacin in the presence of degradation products and its process-related impurities. Acta Chromatogr. 24(1), 23–36.